Market Signal Briefing

Cipher Digital Inc. (CIFR - Free Report) closed the most recent trading day at $14.67, moving -2.78% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 1.36% for the day. Meanwhile, the Dow lost 1.64%, and the Nasdaq, a tech-heavy index, lost 1.46%.

Coming into today, shares of the company had lost 3.52% in the past month. In that same time, the Business Services sector lost 1.11%, while the S&P 500 lost 1.76%.

The investment community will be paying close attention to the earnings performance of Cipher Digital Inc. in its upcoming release. The company's upcoming EPS is projected at -$0.27, signifying a 145.45% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $34.56 million, indicating a 29.41% decline compared to the corresponding quarter of the prior year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.9 per share and a revenue of $236.95 million, indicating changes of +58.14% and +5.81%, respectively, from the former year.

Investors should also take note of any recent adjustments to analyst estimates for Cipher Digital Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Cipher Digital Inc. is currently sporting a Zacks Rank of #3 (Hold).

The Technology Services industry is part of the Business Services sector. With its current Zacks Industry Rank of 179, this industry ranks in the bottom 27% of all industries, numbering over 250.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Prologis (PLD - Free Report) closed the most recent trading day at $131.20, moving -1.51% from the previous trading session. This move lagged the S&P 500's daily loss of 1.36%. Meanwhile, the Dow experienced a drop of 1.64%, and the technology-dominated Nasdaq saw a decrease of 1.46%.

Heading into today, shares of the industrial real estate developer had lost 6.04% over the past month, lagging the Finance sector's loss of 5.19% and the S&P 500's loss of 1.76%.

Analysts and investors alike will be keeping a close eye on the performance of Prologis in its upcoming earnings disclosure. The company's earnings report is set to go public on April 16, 2026. The company's upcoming EPS is projected at $1.48, signifying a 4.23% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $2.11 billion, showing a 6.41% escalation compared to the year-ago quarter.

For the full year, the Zacks Consensus Estimates are projecting earnings of $6.12 per share and revenue of $8.64 billion, which would represent changes of +5.34% and +5.94%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Prologis. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.08% higher within the past month. Prologis is holding a Zacks Rank of #3 (Hold) right now.

Investors should also note Prologis's current valuation metrics, including its Forward P/E ratio of 21.77. This denotes a premium relative to the industry average Forward P/E of 11.72.

We can also see that PLD currently has a PEG ratio of 3.15. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. REIT and Equity Trust - Other stocks are, on average, holding a PEG ratio of 2.5 based on yesterday's closing prices.

The REIT and Equity Trust - Other industry is part of the Finance sector. Currently, this industry holds a Zacks Industry Rank of 139, positioning it in the bottom 44% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Lucid Group (LCID - Free Report) ended the recent trading session at $9.95, demonstrating a -3.59% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 1.36% for the day. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy Nasdaq depreciated by 1.46%.

The an electric vehicle automaker's stock has climbed by 4.03% in the past month, exceeding the Auto-Tires-Trucks sector's loss of 6.26% and the S&P 500's loss of 1.76%.

Market participants will be closely following the financial results of Lucid Group in its upcoming release. The company is expected to report EPS of -$2.37, up 1.25% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $471.83 million, showing a 100.74% escalation compared to the year-ago quarter.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$9.83 per share and revenue of $2.26 billion. These totals would mark changes of +18.69% and +67.28%, respectively, from last year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Lucid Group. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 8.78% fall in the Zacks Consensus EPS estimate. Lucid Group is currently sporting a Zacks Rank of #3 (Hold).

The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. Currently, this industry holds a Zacks Industry Rank of 159, positioning it in the bottom 36% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

March 18, 2026 19:17 ET  | Source: Preferred Bank

LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) -- Preferred Bank (NASDAQ: PFBC), one of the larger independent commercial banks in California, today reported that the Board of Directors has declared a quarterly cash dividend of $0.80 per share, payable on April 21, 2026 to holders of record on April 7, 2026.

About Preferred Bank

Preferred Bank is one of the larger independent commercial banks headquartered in California. The Bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Bank conducts its banking business from its main office in Los Angeles, California, and through twelve full-service branch banking offices in California (Alhambra, Century City, City of Industry, Torrance, Arcadia, Irvine (2), Diamond Bar, Pico Rivera, Tarzana and San Francisco (2)), two branches in New York (Manhattan and Flushing, Queens) and a branch office in the Houston, Texas suburb of Sugar Land. In addition, the Bank also operates a loan production office in Sunnyvale, California. Preferred Bank offers a broad range of deposit and loan products and services to both commercial and consumer customers. The Bank provides personalized deposit services as well as real estate finance, commercial loans and trade finance to small and mid-sized businesses, entrepreneurs, real estate developers, professionals and high net worth individuals. Although originally founded as a Chinese-American Bank, Preferred Bank now derives most of its customers from the diversified mainstream market but does continue to benefit from the significant migration to California of ethnic Chinese from China and other areas of East Asia.

AT THE COMPANY:AT FINANCIAL PROFILES:Edward J. CzajkaJeffrey HaasExecutive Vice PresidentGeneral InformationChief Financial Officer(310) 622-8240(213) [email protected]

Morgan Stanley and Citigroup are among Janus clients that prefer a deal with Trian and General Catalyst

For the quarter ended December 2025, Accelerant Holdings (ARX - Free Report) reported revenue of $248.4 million, representing no change compared to the same period last year. EPS came in at $0.23, compared to $0 in the year-ago quarter.

The reported revenue represents a surprise of -0.03% over the Zacks Consensus Estimate of $248.47 million. With the consensus EPS estimate being $0.16, the EPS surprise was +45.57%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Accelerant Holdings performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net revenue retention: 126% versus 124.4% estimated by three analysts on average.Owned Members: 15 versus the two-analyst average estimate of 15.Mission Members: 31 versus the two-analyst average estimate of 31.Number of Members Total: 280 compared to the 271 average estimate based on two analysts.Independent Members: 234 versus the two-analyst average estimate of 225.Revenues- MGA Operations: $58.9 million compared to the $54.54 million average estimate based on four analysts.Revenues- Exchange Services: $93.4 million versus the four-analyst average estimate of $87.46 million.Revenues- Net Earned Premiums: $82.4 million versus $104.36 million estimated by four analysts on average.Revenues- Underwriting: $110.6 million versus $127.55 million estimated by four analysts on average.Revenues- Net investment income: $13.6 million versus $9.9 million estimated by three analysts on average.Adjusted EBITDA- Exchange Services: $62.6 million versus the three-analyst average estimate of $58.37 million.Adjusted EBITDA- MGA Operations: $22.8 million compared to the $19.2 million average estimate based on three analysts.View all Key Company Metrics for Accelerant Holdings here>>>

Shares of Accelerant Holdings have returned +11% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

March 18, 2026 19:34 ET  | Source: Vaxcyte, Inc.

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026

At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and Immunoglobulin G Immune Responses for All 31 Serotypes and Was Observed to be Well Tolerated with a Safety Profile Similar to Prevnar 20®

Results Further Validate Potential of Vaxcyte’s Carrier-Sparing Platform to Deliver Broadest-Spectrum PCV Candidates that Provide Protection Against Both Currently Circulating and Historically Prevalent Serotypes

VAX-31 is Designed to Cover ~95% of Invasive Pneumococcal Disease (IPD) and ~88% of Pneumococcal Pneumonia in U.S. Adults Aged 50 and Older, with Potential to Provide an Incremental 14-34% Broader IPD Coverage and 19-31% Broader Pneumonia Coverage than Standard-of-Care Vaccines

SAN CARLOS, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced the publication of results from the positive VAX-31 adult Phase 1/2 clinical study in the journal The Lancet Infectious Diseases. The study evaluated the safety, tolerability and immunogenicity of VAX-31, the Company’s next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumonia compared to one of the current standard-of-care vaccines, Prevnar 20® (PCV20), in healthy adults aged 50 years and older. Based on the positive results of this Phase 1/2 study, VAX-31 is currently being evaluated in the OPUS Phase 3 adult program.

The study results showed that VAX-31 was observed to be well tolerated and demonstrated a safety profile similar to PCV20 through the full six-month evaluation period at all doses studied. At all doses studied, VAX-31 demonstrated robust opsonophagocytic activity (OPA) and immunoglobulin G (IgG) immune responses, with high geometric mean concentrations (GMCs) across all 31 serotypes. The VAX-31 High Dose, which is currently being evaluated in the OPUS Phase 3 program, met or exceeded the OPA response non-inferiority criteria¹ for all 20 serotypes common with PCV20 and met the superiority criteria² for the 11 incremental serotypes unique to VAX-31 and not in PCV20. The VAX-31 High Dose average OPA immune responses were greater for 18 of 20 serotypes compared to PCV20 (geometric mean ratio (GMR) greater than 1.0), with seven of these serotypes achieving statistically higher immune responses3 compared to PCV20.

“The publication of these data, including both the OPA and IgG results, in The Lancet Infectious Diseases further affirms the potential of our site-specific, carrier-sparing platform to deliver the broadest-spectrum PCVs to provide protection against both currently circulating and historically prevalent serotypes,” said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte. “Based on the strength of the unprecedented results from this study, we advanced VAX-31 into a comprehensive Phase 3 adult program and believe we are uniquely positioned to set a new standard by which future adult pneumococcal vaccines will be measured. Through the OPUS Phase 3 trials, we are aiming to expand the breadth of disease and serotype coverage while ensuring immunogenicity levels remain high to ensure durable protection and deliver a next-generation PCV with a best-in-class profile.”

“The published results provide validation of VAX-31’s safety profile and robust immune responses across all 31 serotypes,” said Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte. “These data directly informed the design of our comprehensive OPUS Phase 3 program, including the decision to advance the VAX-31 High Dose and the structure of our pivotal, noninferiority trial that includes head-to-head comparisons of VAX-31 to both PCV20 and Capvaxive® (PCV21). This OPUS Phase 3 program is intended to support a planned Biologics License Application, subject to study outcomes.”

About the VAX-31 Phase 1/2 Adult Study
The VAX-31 Phase 1/2 clinical study was a randomized, observer-blind, active-controlled, dose-finding study that evaluated the safety, tolerability and immunogenicity of a single injection of VAX-31 at three dose levels (Low, Middle and High) compared to PCV20 in 1,015 healthy adults aged 50 years and older. The High Dose is currently being evaluated in the comprehensive OPUS Phase 3 adult clinical program.

Safety and Tolerability Findings:

VAX-31 was observed to be well tolerated and demonstrated a safety profile similar to PCV20 at all doses studied.Frequently reported local and systemic reactions were generally mild-to-moderate, resolving within several days of vaccination, with no meaningful differences observed across the cohorts. No serious adverse events were considered to be related to study vaccines. Immunogenicity Findings:

VAX-31 demonstrated robust OPA immune responses for all 31 serotypes at all doses studied, and all three doses were considered advanceable to Phase 3.At the High and Middle Doses, VAX-31 met or exceeded regulatory immunogenicity criteria for all 31 serotypes and, at the Low Dose, for 29 of 31 serotypes.For the 20 serotypes common with PCV20 (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F): High Dose: All 20 serotypes met OPA response non-inferiority criteria; 18 of 20 serotypes had a GMR greater than 1.0 and seven serotypes achieved statistically higher immune responses compared to PCV20.Middle Dose: All 20 serotypes met OPA response non-inferiority criteria; 13 of 20 serotypes had a GMR greater than 1.0 and five serotypes achieved statistically higher immune responses compared to PCV20.Low Dose: 18 of 20 serotypes met OPA response non-inferiority criteria; eight of 20 serotypes had a GMR greater than 1.0 and three serotypes achieved statistically higher immune responses compared to PCV20. For all 11 additional serotypes unique to VAX-31 (2, 7C, 9N, 15A, 16F, 17F, 20B, 23A, 23B, 31, 35B), and not in PCV20, all three doses met superiority criteria.At all doses studied, VAX-31 demonstrated high IgG GMCs across all 31 serotypes, and IgG GMC responses were consistent with the immune response profile observed in the OPA analyses. About Pneumococcal Disease
Pneumococcal disease (PD) is an infection caused by Streptococcus pneumoniae bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. In the United States, pneumococcal pneumonia is estimated to result in approximately 225,000 adult hospitalizations each year. Streptococcus pneumoniae is among the World Health Organization’s top antibiotic-resistant pathogens to be urgently addressed, and the U.S. CDC lists drug-resistant Streptococcus pneumoniae as a “serious threat.” In children under five, Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally. Pneumococci also cause over 50% of all cases of bacterial meningitis in the United States. Antibiotics are used to treat PD, but some strains of the bacteria have developed resistance to treatments. The morbidity and mortality due to PD are significant, particularly for young children and older adults, underscoring the need for a broader-spectrum vaccine.

About VAX-31
VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is designed to prevent serious and sometimes fatal infections caused by Streptococcus pneumoniae, including IPD, pneumonia and otitis media. Specifically, IPD is associated with high case-fatality rates, antibiotic resistance and meningitis. VAX-31 is the broadest-spectrum PCV candidate in the clinic today and has the potential to provide protection against both currently circulating and historically prevalent serotypes. VAX-31 is designed to increase coverage, in a single vaccine, to approximately 95% of IPD and approximately 88% of pneumococcal pneumonia circulating in adults in the United States aged 50 and older. This disease coverage has the potential to result in VAX-31 providing an incremental 14-34% of coverage for IPD and an incremental 19-31% of coverage for pneumococcal pneumonia over current standard-of-care adult PCVs. In U.S. children, it is designed to cover approximately 92% of IPD4 and approximately 96% of acute otitis media5 due to Streptococcus pneumoniae. This disease coverage has the potential to result in VAX-31 providing an incremental 23-44% of coverage for IPD and an incremental 35-62% of coverage for otitis media over current standard-of-care infant PCVs.

In May 2025, the FDA expanded the Breakthrough Therapy designation (BTD) for VAX-31 to include the prevention of pneumonia caused by Streptococcus pneumoniae in addition to the prevention of IPD in adults based on the positive topline results from the VAX-31 adult Phase 1/2 study indicating that VAX-31 may demonstrate substantial improvement over existing therapies.

About Vaxcyte 
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s carrier-sparing platform and PCV candidates, including breadth of coverage, the ability to deliver potentially best-in-class PCVs, the ability to improve upon the standard-of-care, and the ability to significantly reduce the burden of disease by expanding coverage against currently and historically circulating strains while maintaining robust immune response; the design, timing of initiation, progress and expected results of Vaxcyte’s clinical trials and regulatory plans; the demand for Vaxcyte’s vaccine candidates; and other statements that are not historical fact. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “on track,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K filed with the SEC on February 24, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Readers should not rely upon the information in this press release as current or accurate after its publication date.

Contacts:

Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
[email protected]

Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
[email protected]

1Lower bound of the 2-sided 95% confidence interval of the OPA geometric mean ratio is greater than 0.5.
2Lower bound of the 2-sided 95% confidence interval of the difference in the proportions of participants with a ≥4-fold increase from Day 1 to Month 1 is greater than 10%, and lower bound of the 2-sided 95% confidence interval of the OPA geometric mean ratio is greater than 2.0.
3Lower bound of the 2-sided 95% confidence interval of the OPA geometric mean ratio is greater than 1.0.
4In U.S. children under five years of age: CDC 2023 Active Bacterial Core (ABC) Surveillance data.
5In U.S. children five years of age or under: Grant LR et al., FrontPediatr.2024;12:1383748. Serotype percentages reflect 2017–2021 data (Supplemental Table 1). 

A well-received presentation at a key industry conference and an analyst's price target bump made Lumentum Holdings (LITE +7.89%) a popular stock on Wednesday. Shares of the photonics company rose in excess of 6% in reaction to these developments.

Solid momentum for Lumentum Lumentum held an investor briefing at this year's Optical Fiber Communication Conference (OFC), an event marked by bullish pronouncements from numerous company executives about the future of the industry. Many were excited about supplying goods for the exploding build-out of artificial intelligence (AI).

Image source: Getty Images.

Lumentum's event prompted one analyst in particular, Stifel's Ruben Roy, to reiterate his optimistic take on the company's proximate future. According to reports, he cited the briefing in his Wednesday morning update on the stock. He noted several encouraging forecasts from management, including its estimate of a $90 billion total addressable market for optical AI products by 2030.

Roy also noted Lumentum's announcement of a multi-year contract with one large customer that the company did not name. This deal, covering optical circuit switching (OCS) products, is worth billions of dollars, management said.

The analyst reiterated his buy recommendation on Lumenteum and his $800 per share price target.

Today's Change

(

7.89

%) $

51.23

Current Price

$

700.79

Seeing a bright future Lumentum stock has been on quite a tear so far this year, and that's understandable given its role as a reliable supplier of goods essential to the smooth functioning of AI. Although the company isn't the bargain it was before hordes of investors piled into it, it's very well positioned to reap the long-term rewards of operating in the right business at the right time in history.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Lumentum. The Motley Fool has a disclosure policy.

In Brief

Posted:

4:42 PM PDT · March 18, 2026

Image Credits:Carol Yepes / Getty Images An AI agent went rogue at Meta, exposing sensitive company and user data to employees who did not have permission to access.

Per an incident report, which was viewed and reported on by The Information, a Meta employee posted on an internal forum asking for help with a technical question — which is a standard action. However, another engineer asked an AI agent to help analyze the question, and the agent ended up posting a response without asking the engineer for permission to share it. Meta confirmed the incident to The Information.

As it turns out, the AI agent did not give good advice. The employee who asked the question ended up taking actions based on the agent’s guidance, which inadvertently made massive amounts of company and user-related data available to engineers who were not authorized to access it for two hours.

Meta deemed the incident a “Sev 1,” which is the second-highest level of severity in the company’s internal system for measuring security issues.

Rogue AI agents have already posed a problem at Meta. Summer Yue, a safety and alignment director at Meta Superintelligence, posted on X last month describing how her OpenClaw agent ended up deleting her entire inbox, even though she told it to confirm with her before taking any action.

Still, Meta seems bullish on the potential for agentic AI. Just last week, Meta bought Moltbook, a Reddit-like social media site for OpenClaw agents to communicate with one another.

Topics

Subscribe for the industry’s biggest tech news

Latest in AI

MARKER THERAPEUTICS, INC. (MRKR - Free Report) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +80.49%. A quarter ago, it was expected that this company would post a loss of $0.69 per share when it actually produced a loss of $0.12, delivering a surprise of +82.61%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

MARKER THERAPEUTICS, which belongs to the Zacks Medical - Drugs industry, posted revenues of $1.1 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 83.83%. This compares to year-ago revenues of $2.25 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

MARKER THERAPEUTICS shares have lost about 8.7% since the beginning of the year versus the S&P 500's decline of 1.9%.

What's Next for MARKER THERAPEUTICS?While MARKER THERAPEUTICS has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for MARKER THERAPEUTICS was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.22 on $0.6 million in revenues for the coming quarter and -$1.86 on $2.3 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, electroCore, Inc. (ECOR - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on March 19.

This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

electroCore, Inc.'s revenues are expected to be $9.26 million, up 31.4% from the year-ago quarter.

HomeStock IdeasLong IdeasConsumer Staples Analysis

SummaryBritish American Tobacco p.l.c. (BTI) offers deep value, trading at a forward P/E of ~12x with a 5-6% dividend yield, despite robust cash flows.BTI's revenue and margins remain stable, with gross margins near 82% and FCF yield above 10%, underpinned by resilient global demand and pricing power.Transition to 'digital nicotine' (vapes, heated tobacco) offsets declining cigarette sales; BTI is closing the innovation gap with Philip Morris.Risks from regulatory shocks are already priced in, making BTI a defensive 'concrete bunker' for portfolios facing stagflation and market instability.Editor's note: Seeking Alpha is proud to welcome Elina Selianska as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.

1 Follower

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- If you suffered a loss on your investment in Plug Power, Inc. (“Plug Power” or the “Company”) (NASDAQ:PLUG), contact Lauren Molinaro by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until April 3, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of January 17, 2025 through November 13, 2025, inclusive (“the Class Period”). The lawsuit alleges that (i) Plug Power had materially overstated the likelihood that funds attributed to the DOE Loan would ultimately become available to Plug Power, and/or that Plug Power would ultimately construct the hydrogen production facilities necessary to receive those funds and (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside.

On October 7, 2025, Plug Power issued a press release and filed a current report on Form 8-K with the United States Securities and Exchange Commission (“SEC”) announcing that Defendant Andrew Marsh would step down from his role as the Company’s Chief Executive Officer, “effective as of the date [Plug Power] files its [2025] Annual Report”, and that Sanjay Shrestha would step down from his role as the Company’s President, “effective as of October 10, 2025[.]” Plug Power concurrently announced the appointment of Chief Revenue Officer Jose Luis Crespo to both roles. On this news, the price of Plug Power shares declined by $0.26 per share, or approximately 6.3%, from $4.13 per share on October 6, 2025 to close at $3.87 on October 7, 2025.

Then, on October 8, 2025, Plug Power issued a press release announcing it had entered into an agreement inducing the immediate exercise of the entirety of its outstanding warrants issued in the offering to a single institutional investor. Plug Power announced that this agreement yielded gross proceeds of approximately $370 million. In consideration for the immediate exercise of the offering warrants, Plug Power granted the investor new warrants to purchase a total of 185,430,464 million shares of common stock with an exercise price of $7.75, representing a premium of approximately 100% to Plug Power’s last closing stock price on October 7, 2025. Plug Power stated that it would receive approximately $1.4 billion in gross proceeds if the new warrants are fully exercised on a cash basis and stated that the Company intended to use proceeds from the new warrants “for working capital and general corporate purposes.” On this news, the price of Plug Power shares declined by $0.21 per share, or approximately 5.4%, from $3.87 per share on October 8, 2025 to close at $3.66 on October 9, 2025.

Then, on November 10, 2025, Plug Power issued a press release reporting its financial results for the quarter ended September 30, 2025, and filed a quarterly report on Form 10-Q with the SEC that reported the same. That same day, Plug Power held a related conference call to discuss those results. During the call, Defendants announced that they expected to generate more than $275 million in liquidity after signing a nonbinding letter of intent to monetize their electricity rights in New York and one other location in partnership with a major U.S. data center developer, and that “[a]s a result, we have suspended activities under the DOE loan program, allowing us to redeploy capital.” On this news, the price of Plug Power shares declined by $0.09 per share, or approximately 3.4%, from $2.65 per share on November 7, 2025 to close at $2.56 on November 10, 2025.

Then, on November 13, 2025, The Washington Examiner reported that Plug Power “confirmed . . . . that it suspended activities” on “its plans to construct six facilities to produce and liquefy zero or low-carbon hydrogen, putting at risk” the $1.66 billion DOE Loan it closed in January. On this news, the price of Plug Power shares declined by $0.48 per share, or approximately 17.6%, from $2.73 per share on November 12, 2025 to close at $2.25 on November 14, 2025.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Plug Power securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

Red Cat Holdings, Inc. (RCAT) Q4 2025 Earnings Call March 18, 2026 4:30 PM EDT

Company Participants

Ankit Hira
Jeffrey Thompson - Founder, President, CEO & Chairman
Christian Ericson - Chief Operating Officer
Christian Morrison - Chief Financial Officer

Conference Call Participants

Austin Bohlig - Needham & Company, LLC, Research Division
Mike Latimore - Northland Capital Markets, Research Division

Presentation

Operator

Greetings, and welcome to the Red Cat quarterly earnings. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host Ankit Hira, Investor Relations. Thank you, Ankit. You may begin.

Ankit Hira

Good afternoon, and welcome to Red Cat's Fourth Quarter and Full Year 2025 Earnings Call. Joining us are Red Cat's CEO, Jeff Thompson; COO, Chris Ericson; and CFO, Christian Morrison.

Please note that certain information discussed on the call today will include forward-looking statements for our future events and Red Cat's business strategy and future financial and operating performance. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict and may cause actual results to differ materially from those stated or implied by those statements.

Certain risks, uncertainties and assumptions are discussed in Red Cat's SEC filings, including its most recent annual report on Form 10-K and other SEC filings. These forward-looking statements reflect management's beliefs, estimates and predictions as of the date of this live broadcast, March 18, 2026, and Red Cat undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.

In addition, our comments on the call today will contain references to non-GAAP financial measures such as adjusted EBITDA and key business metrics. Non-GAAP measures should be viewed in addition to and not as an alternative for the company's

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline.

SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the REGENXBIO class action, go to https://rosenlegal.com/submit-form/?case_id=53421 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things, REGENXBIO's positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the REGENXBIO class action, go to https://rosenlegal.com/submit-form/?case_id=53421 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289103

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

In the latest trading session, Western Digital (WDC - Free Report) closed at $304.90, marking a -2.84% move from the previous day. The stock's change was less than the S&P 500's daily loss of 1.36%. Elsewhere, the Dow lost 1.64%, while the tech-heavy Nasdaq lost 1.46%.

Shares of the maker of hard drives for businesses and personal computers witnessed a gain of 10.45% over the previous month, beating the performance of the Computer and Technology sector with its loss of 0.24%, and the S&P 500's loss of 1.76%.

The upcoming earnings release of Western Digital will be of great interest to investors. In that report, analysts expect Western Digital to post earnings of $2.34 per share. This would mark year-over-year growth of 72.06%. Meanwhile, the latest consensus estimate predicts the revenue to be $3.23 billion, indicating a 40.72% increase compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.96 per share and a revenue of $12.43 billion, signifying shifts of +81.74% and -6.38%, respectively, from the last year.

Any recent changes to analyst estimates for Western Digital should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.11% higher. Right now, Western Digital possesses a Zacks Rank of #1 (Strong Buy).

Looking at valuation, Western Digital is presently trading at a Forward P/E ratio of 35.02. This represents a premium compared to its industry average Forward P/E of 14.34.

Also, we should mention that WDC has a PEG ratio of 0.69. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Computer- Storage Devices industry stood at 1.4 at the close of the market yesterday.

The Computer- Storage Devices industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 23, positioning it in the top 10% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow WDC in the coming trading sessions, be sure to utilize Zacks.com.

Upstart Holdings, Inc. (UPST - Free Report) closed the most recent trading day at $25.83, moving -7.19% from the previous trading session. This change lagged the S&P 500's 1.36% loss on the day. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy Nasdaq depreciated by 1.46%.

Shares of the company witnessed a loss of 12.95% over the previous month, trailing the performance of the Finance sector with its loss of 5.19%, and the S&P 500's loss of 1.76%.

Investors will be eagerly watching for the performance of Upstart Holdings, Inc. in its upcoming earnings disclosure. On that day, Upstart Holdings, Inc. is projected to report earnings of $0.38 per share, which would represent year-over-year growth of 26.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $290.01 million, indicating a 35.92% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.37 per share and revenue of $1.4 billion, indicating changes of +36.21% and +34.52%, respectively, compared to the previous year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Upstart Holdings, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Upstart Holdings, Inc. boasts a Zacks Rank of #5 (Strong Sell).

With respect to valuation, Upstart Holdings, Inc. is currently being traded at a Forward P/E ratio of 11.77. This signifies a premium in comparison to the average Forward P/E of 10.61 for its industry.

It is also worth noting that UPST currently has a PEG ratio of 0.29. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Financial - Miscellaneous Services industry stood at 0.82 at the close of the market yesterday.

The Financial - Miscellaneous Services industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 146, which puts it in the bottom 41% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

QuickLogic (QUIK - Free Report) ended the recent trading session at $9.26, demonstrating a +2.09% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 1.36% for the day. Elsewhere, the Dow lost 1.64%, while the tech-heavy Nasdaq lost 1.46%.

Shares of the maker of chips for mobile and portable electronics manufacturers witnessed a gain of 21.75% over the previous month, beating the performance of the Computer and Technology sector with its loss of 0.24%, and the S&P 500's loss of 1.76%.

The upcoming earnings release of QuickLogic will be of great interest to investors. The company's upcoming EPS is projected at -$0.06, signifying a 14.29% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $5.5 million, showing a 27.31% escalation compared to the year-ago quarter.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0 per share and a revenue of $24.7 million, representing changes of +100% and +79.32%, respectively, from the prior year.

Any recent changes to analyst estimates for QuickLogic should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 11.11% lower within the past month. Right now, QuickLogic possesses a Zacks Rank of #4 (Sell).

The Electronics - Semiconductors industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 85, finds itself in the top 35% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

On Holding (ONON - Free Report) closed the most recent trading day at $39.05, moving -1.86% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 1.36%. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy Nasdaq depreciated by 1.46%.

Coming into today, shares of the running-shoe and apparel company had lost 14.72% in the past month. In that same time, the Retail-Wholesale sector lost 0.82%, while the S&P 500 lost 1.76%.

Market participants will be closely following the financial results of On Holding in its upcoming release. The company is predicted to post an EPS of $0.36, indicating a 56.52% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $1.06 billion, up 31.76% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $1.67 per share and a revenue of $4.53 billion, demonstrating changes of +72.16% and +24.54%, respectively, from the preceding year.

It is also important to note the recent changes to analyst estimates for On Holding. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.53% lower. At present, On Holding boasts a Zacks Rank of #3 (Hold).

With respect to valuation, On Holding is currently being traded at a Forward P/E ratio of 23.83. This denotes a premium relative to the industry average Forward P/E of 16.28.

Meanwhile, ONON's PEG ratio is currently 0.66. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Retail - Apparel and Shoes stocks are, on average, holding a PEG ratio of 1.38 based on yesterday's closing prices.

The Retail - Apparel and Shoes industry is part of the Retail-Wholesale sector. At present, this industry carries a Zacks Industry Rank of 79, placing it within the top 33% of over 250 industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

In the latest trading session, Newmont Corporation (NEM - Free Report) closed at $106.54, marking a -4.05% move from the previous day. This change lagged the S&P 500's daily loss of 1.36%. At the same time, the Dow lost 1.64%, and the tech-heavy Nasdaq lost 1.46%.

Shares of the gold and copper miner witnessed a loss of 9.21% over the previous month, trailing the performance of the Basic Materials sector with its loss of 5.3%, and the S&P 500's loss of 1.76%.

The investment community will be closely monitoring the performance of Newmont Corporation in its forthcoming earnings report. The company is predicted to post an EPS of $2.07, indicating a 65.6% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $6.53 billion, indicating a 30.38% upward movement from the same quarter last year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.79 per share and a revenue of $26.27 billion, indicating changes of +27.58% and +15.88%, respectively, from the former year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Newmont Corporation. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 6.64% higher. At present, Newmont Corporation boasts a Zacks Rank of #3 (Hold).

In terms of valuation, Newmont Corporation is presently being traded at a Forward P/E ratio of 12.63. This indicates a premium in contrast to its industry's Forward P/E of 10.68.

We can also see that NEM currently has a PEG ratio of 0.86. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Mining - Gold industry held an average PEG ratio of 1.18.

The Mining - Gold industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 46, which puts it in the top 19% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Kinder Morgan (KMI - Free Report) ended the recent trading session at $32.61, demonstrating a -1.98% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Meanwhile, the Dow lost 1.64%, and the Nasdaq, a tech-heavy index, lost 1.46%.

The oil and natural gas pipeline and storage company's shares have seen an increase of 3.55% over the last month, not keeping up with the Oils-Energy sector's gain of 10.02% and outstripping the S&P 500's loss of 1.76%.

Investors will be eagerly watching for the performance of Kinder Morgan in its upcoming earnings disclosure. The company is expected to report EPS of $0.37, up 8.82% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $4.51 billion, showing a 6.33% escalation compared to the year-ago quarter.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.39 per share and revenue of $17.75 billion, indicating changes of +6.92% and +4.82%, respectively, compared to the previous year.

Any recent changes to analyst estimates for Kinder Morgan should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.19% higher. Kinder Morgan presently features a Zacks Rank of #3 (Hold).

In terms of valuation, Kinder Morgan is currently trading at a Forward P/E ratio of 24.01. This indicates a premium in contrast to its industry's Forward P/E of 19.41.

One should further note that KMI currently holds a PEG ratio of 3.07. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Oil and Gas - Production and Pipelines industry had an average PEG ratio of 1.63 as trading concluded yesterday.

The Oil and Gas - Production and Pipelines industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 179, putting it in the bottom 27% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Emerson Electric (EMR - Free Report) closed the most recent trading day at $129.88, moving -1.97% from the previous trading session. This change lagged the S&P 500's daily loss of 1.36%. On the other hand, the Dow registered a loss of 1.64%, and the technology-centric Nasdaq decreased by 1.46%.

Shares of the maker of process controls systems, valves and analytical instruments have depreciated by 10.99% over the course of the past month, underperforming the Industrial Products sector's loss of 8.71%, and the S&P 500's loss of 1.76%.

The upcoming earnings release of Emerson Electric will be of great interest to investors. In that report, analysts expect Emerson Electric to post earnings of $1.55 per share. This would mark year-over-year growth of 4.73%. Meanwhile, the latest consensus estimate predicts the revenue to be $4.62 billion, indicating a 4.32% increase compared to the same quarter of the previous year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.5 per share and a revenue of $18.98 billion, indicating changes of +8.33% and +5.36%, respectively, from the former year.

Investors should also take note of any recent adjustments to analyst estimates for Emerson Electric. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.12% lower. Emerson Electric is currently sporting a Zacks Rank of #3 (Hold).

With respect to valuation, Emerson Electric is currently being traded at a Forward P/E ratio of 20.39. Its industry sports an average Forward P/E of 24.84, so one might conclude that Emerson Electric is trading at a discount comparatively.

Also, we should mention that EMR has a PEG ratio of 2.11. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. EMR's industry had an average PEG ratio of 1.87 as of yesterday's close.

The Manufacturing - Electronics industry is part of the Industrial Products sector. With its current Zacks Industry Rank of 62, this industry ranks in the top 26% of all industries, numbering over 250.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

In the latest close session, IonQ, Inc. (IONQ - Free Report) was down 2.79% at $32.38. This change lagged the S&P 500's 1.36% loss on the day. Meanwhile, the Dow lost 1.64%, and the Nasdaq, a tech-heavy index, lost 1.46%.

Heading into today, shares of the company had gained 0.39% over the past month, outpacing the Computer and Technology sector's loss of 0.24% and the S&P 500's loss of 1.76%.

The investment community will be closely monitoring the performance of IonQ, Inc. in its forthcoming earnings report. The company is forecasted to report an EPS of -$0.47, showcasing a 235.71% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $49.66 million, indicating a 555.97% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.57 per share and revenue of $237.08 million, indicating changes of +13.74% and +82.34%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for IonQ, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 9.63% higher. As of now, IonQ, Inc. holds a Zacks Rank of #3 (Hold).

The Computer - Integrated Systems industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 24, which puts it in the top 10% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Brinker International (EAT - Free Report) closed the most recent trading day at $140.05, moving -1.91% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 1.36%. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy Nasdaq depreciated by 1.46%.

The operator of restaurant chains Chili's Grill & Bar and Maggiano's Little Italy's stock has dropped by 12.59% in the past month, falling short of the Retail-Wholesale sector's loss of 0.82% and the S&P 500's loss of 1.76%.

Market participants will be closely following the financial results of Brinker International in its upcoming release. In that report, analysts expect Brinker International to post earnings of $2.86 per share. This would mark year-over-year growth of 7.52%. At the same time, our most recent consensus estimate is projecting a revenue of $1.48 billion, reflecting a 3.91% rise from the equivalent quarter last year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $10.68 per share and revenue of $5.81 billion, indicating changes of +20% and +7.93%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for Brinker International. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.19% upward. Brinker International is currently sporting a Zacks Rank of #2 (Buy).

From a valuation perspective, Brinker International is currently exchanging hands at a Forward P/E ratio of 13.37. This represents a discount compared to its industry average Forward P/E of 20.22.

One should further note that EAT currently holds a PEG ratio of 1.01. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Retail - Restaurants industry held an average PEG ratio of 1.92.

The Retail - Restaurants industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 163, which puts it in the bottom 34% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Five Below (FIVE - Free Report) reported $1.73 billion in revenue for the quarter ended January 2026, representing a year-over-year increase of 24.3%. EPS of $4.31 for the same period compares to $3.48 a year ago.

The reported revenue represents a surprise of +1.14% over the Zacks Consensus Estimate of $1.71 billion. With the consensus EPS estimate being $3.99, the EPS surprise was +8.02%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Five Below performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Comparable Sales: 15.4% compared to the 14.5% average estimate based on six analysts.Total stores at end of period: 1,921 versus 1,921 estimated by five analysts on average.New Store Openings: 14 compared to the 14 average estimate based on four analysts.View all Key Company Metrics for Five Below here>>>

Shares of Five Below have returned +0.7% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.